- Home
- AMLX vs TLRY Comparison
AMLX vs TLRY Comparison
Compare AMLX & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- TLRY
- Stock Information
- Founded
- AMLX 2014
- TLRY N/A
- Country
- AMLX United States
- TLRY Canada
- Employees
- AMLX N/A
- TLRY N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- AMLX Health Care
- TLRY Health Care
- Exchange
- AMLX Nasdaq
- TLRY Nasdaq
- Market Cap
- AMLX 749.9M
- TLRY 624.7M
- IPO Year
- AMLX 2022
- TLRY 2018
- Fundamental
- Price
- AMLX $10.20
- TLRY $1.19
- Analyst Decision
- AMLX Strong Buy
- TLRY Buy
- Analyst Count
- AMLX 7
- TLRY 4
- Target Price
- AMLX $12.29
- TLRY $1.58
- AVG Volume (30 Days)
- AMLX 1.3M
- TLRY 97.7M
- Earning Date
- AMLX 08-07-2025
- TLRY 10-09-2025
- Dividend Yield
- AMLX N/A
- TLRY N/A
- EPS Growth
- AMLX N/A
- TLRY N/A
- EPS
- AMLX N/A
- TLRY N/A
- Revenue
- AMLX N/A
- TLRY $821,309,000.00
- Revenue This Year
- AMLX N/A
- TLRY $7.44
- Revenue Next Year
- AMLX N/A
- TLRY $4.66
- P/E Ratio
- AMLX N/A
- TLRY N/A
- Revenue Growth
- AMLX N/A
- TLRY 4.10
- 52 Week Low
- AMLX $2.09
- TLRY $0.35
- 52 Week High
- AMLX $10.20
- TLRY $1.88
- Technical
- Relative Strength Index (RSI)
- AMLX 69.71
- TLRY 55.93
- Support Level
- AMLX $9.15
- TLRY $1.10
- Resistance Level
- AMLX $10.06
- TLRY $1.50
- Average True Range (ATR)
- AMLX 0.54
- TLRY 0.12
- MACD
- AMLX 0.12
- TLRY -0.02
- Stochastic Oscillator
- AMLX 98.53
- TLRY 33.33
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. USA exposure consists of CBD products and alcohol.